Year: - Any -2023202220212020201920182017 Items per page 102550 Date Title Jun 06, 2023 Summary ToggleSol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada May 12, 2023 Summary ToggleSol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update Mar 20, 2023 Summary ToggleSol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference Mar 10, 2023 Summary ToggleSol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments Jan 27, 2023 Summary ToggleSol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings Jan 27, 2023 Summary ToggleSol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million Nov 10, 2022 Summary ToggleSol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update Oct 03, 2022 Summary ToggleSol-Gel Technologies Appoints Michael Glezin Vice President, Business Development Aug 04, 2022 Summary ToggleSol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update Jun 02, 2022 Summary ToggleGalderma Launches EPSOLAY® Cream, a Medical Advance to Treat Bumps and Blemishes of Rosacea Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last
Year: - Any -2023202220212020201920182017 Items per page 102550 Date Title Jun 06, 2023 Summary ToggleSol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada May 12, 2023 Summary ToggleSol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update Mar 20, 2023 Summary ToggleSol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference Mar 10, 2023 Summary ToggleSol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments Jan 27, 2023 Summary ToggleSol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings Jan 27, 2023 Summary ToggleSol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million Nov 10, 2022 Summary ToggleSol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update Oct 03, 2022 Summary ToggleSol-Gel Technologies Appoints Michael Glezin Vice President, Business Development Aug 04, 2022 Summary ToggleSol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update Jun 02, 2022 Summary ToggleGalderma Launches EPSOLAY® Cream, a Medical Advance to Treat Bumps and Blemishes of Rosacea Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last